[ad_1]
The Ethics and Cancer Committee, a French consultative body, has found no reason to oppose the use of cannabis by adults with a serious illness who claim to benefit from it, even if this benefit does not is not rigorously demonstrated.
A patient with cancer, who claims that the consumption of this product relieves her of intense and chronic pain and nausea, had asked the Committee about the ethical nature or not of the prohibition of cannabis in a therapeutic context.
She compares the current ban to "refusal of care", said Tuesday the Committee chaired by the French professor Axel Kahn, geneticist and honorary president of the University Paris-Descartes.
No harmful effect proved to be serious enough
Despite the "still insufficient data"On the therapeutic effects of cannabis, the Committee focused on whether there are ethical reasons to oppose the use of cannabis by patients who say they are relieved.
"None of the arguments possibly against such consumption appeared to him to be able to continue to ban it."he says.
"In particular, he was unable to identify any adverse effects that were serious enough to counteract such practice by adults with serious, life-threatening illnesses who claim to benefit from it.".
But he recommends not to smoke it and to favor other forms of consumption.
Allow ill people not to use parallel circuits
According to the Committee, whose opinion is available online (ethique-cancer.fr), it should be that access to cannabis or its active substances "may be supervised by the health authorities, in order to provide patients with the necessary guarantees as to the quality, the concentrations and the optimal use of cannabis or its active substances".
This "supervision would also allow sick people to dispense with the use of parallel circuits"to get some and"would also avoid the risk of criminal prosecution for their consumption".
The League Against Cancer is at the origin of the creation of the Ethics and Cancer Committee, installed in 2008 by then French Minister of Health Roselyne Bachelot-Narquin.
An expert committee of the ANSM Medecine Agency will give its first conclusions by the end of the year on the interest of setting up in France access to therapeutic cannabis.
[ad_2]
Source link
